论文部分内容阅读
目的评价静脉应用胺碘酮对室上性心动过速(SVT)患儿的疗效及安全性。方法 60例急诊SVT患者,随机分为观察组(胺碘酮)和对照组(心律平),每组各30例。观察组静脉应用胺碘酮急诊复率,对照组应用心律平急诊复律,观察二组复律成功率,评价安全性。结果胺碘酮组复律成功率为83.3%,心律平组为46.6%,胺碘酮组明显高于心律平组(P<0.01)。胺碘酮治疗前后血压比较,差异无统计学意义(P<0.05)。3例静脉注射过程中出现血压偏低,无需特殊处理,无心动过缓出现,无QT间期延长。心律平组无明显不良反应。结论静脉注射胺碘酮对儿童室上性心动过速的即时疗效好,且较为安全,值得在基层医院推广。
Objective To evaluate the efficacy and safety of intravenous amiodarone in children with supraventricular tachycardia (SVT). Methods Sixty patients with emergency SVT were randomly divided into observation group (amiodarone) and control group (rhythm level), 30 cases in each group. Amiodarone emergency rate in the observation group was administered intravenously, while in the control group, cardioversion emergency procedure was used in the control group. The success rate of cardioversion in the two groups was observed to evaluate the safety. Results The success rate of cardioversion was 83.3% in amiodarone group and 46.6% in rhythmin group, and was significantly higher in amiodarone group than that in rhythm group (P <0.01). Amiodarone blood pressure before and after treatment, the difference was not statistically significant (P <0.05). 3 cases of low blood pressure during intravenous injection, without special treatment, no bradycardia appeared, no QT prolongation. Heart rate group no obvious adverse reactions. Conclusion Intravenous amiodarone has an immediate effect on supraventricular tachycardia in children and is safe and worthy of promotion in primary hospitals.